Cargando…
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the applic...
Autores principales: | Rini, Brian I, Brugarolas, James, Atkins, Michael B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008164/ https://www.ncbi.nlm.nih.gov/pubmed/36898737 http://dx.doi.org/10.1136/jitc-2022-006361 |
Ejemplares similares
-
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020) -
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019) -
The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010) -
Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites
por: Bezwada, Divya, et al.
Publicado: (2023) -
Toward lentiviral vectors for antiangiogenic ocular gene therapy
por: Askou, Anne Louise, et al.
Publicado: (2023)